Khartis Therapeutics
PrivateLast Round
Series B
Aug 13, 2026
Total Funding Raised
$95M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Khartis Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in August 2026.
Khartis Therapeutics is a biotechnology company that develops oral small-molecule medicines for immunological and chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Khartis Therapeutics Comparables
Compare Khartis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sling Therapeutics | 86% | |
| Ethyreal Bio | 81% | |
| Yarrow Bioscience, Inc. | 81% |
For institutional investors. Book with your work email.
Khartis Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Khartis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forge Life Science Partners | Series B |
| Foresite Capital | Series B, Series A |
| Alexandria Venture Investments | Series B |
| Lilly Asia Ventures | Series B, Series A |
| Nextech Invest | Series B, Series A |
| Longwood Fund | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 13, 2026
$50M round led by Forge Life Science Partners.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 13, 2026
Khartis THERAPEUTICS, INC. raises $50M in Series B funding led by Forge Life Science Partners, with Longwood Fund and Alexandria Venture Investments joining existing investors, to advance its oral medicine pipeline in California on Aug 13th '26.
For institutional investors. Book with your work email.
Khartis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Khartis Therapeutics's valuation, stock price, and market status.
Is Khartis Therapeutics a public or private company?
Khartis Therapeutics is a private company.
What is the current stock price of Khartis Therapeutics?
Khartis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Khartis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Khartis Therapeutics worth (valuation)?
Valuation information for Khartis Therapeutics is not publicly available.
Can I buy Khartis Therapeutics stock?
Khartis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Khartis Therapeutics's last funding round?
Khartis Therapeutics's most recent funding round was Series B on August 13, 2026.
Who are the main investors in Khartis Therapeutics?
Key investors in Khartis Therapeutics include Forge Life Science Partners.
Will Khartis Therapeutics IPO soon?
No public IPO plans have been announced for Khartis Therapeutics.
How can I track Khartis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Khartis Therapeutics's shares on secondary markets.